Bristol Myers Opdivo Wins cHL Nod; Lilly Cuts Zepbound Price

New oncology approvals and GLP-1 pricing moves highlight pharma sector activity

Healthcare Market Overview

Healthcare equities showed mixed performance with several large-cap names experiencing share price weakness prompting valuation reassessments. $BMY posted a 7.5% year-to-date gain despite recent declines, while $TMO faces a 19.9% year-to-date decline and $ABT showed recent volatility after pressure in the past month and quarter. Leadership changes emerged as $BMY CEO Christopher S. Boerner joined Colgate-Palmolive's board, bringing healthcare expertise to the consumer products company.

Big Pharma & Biotech

$BMY received new U.S. and European Union approvals for Opdivo in classical Hodgkin Lymphoma covering adult and pediatric patients, expanding the drug's reach in hematology-oncology for newly diagnosed and relapsed or refractory cases. $LLY announced Zepbound will be available for self-pay starting at $299 per month for the 2.5 mg dose through LillyDirect and major pharmacies, expanding access for uninsured patients. $REGN saw its modeled fair value estimate lifted from $821.12 to $873.78 per share as analysts debate how much of the Dupixent franchise and pipeline is already priced into shares.

MedTech & Devices

Tandem Diabetes Care outlined plans for a shift toward the pharmacy channel and targets a 65% gross margin with a 2026 Mobi tubeless launch, expecting the moves to reshape revenue mix and margin profile over the coming years. The company is expanding its product portfolio and international presence as part of its growth strategy. $ABT faced investor reassessment following recent share price weakness, though the stock has delivered a 14.96% one-year total shareholder return despite volatility.

FDA & Regulation

The FDA and European Union granted Opdivo expanded approvals in classical Hodgkin Lymphoma, providing new treatment options for pediatric and young adult groups with limited alternatives. The regulatory decisions broaden $BMY's oncology portfolio and extend its hematology presence. Drug pricing reforms continue to influence company strategies, with $LLY's direct-to-consumer pricing model for Zepbound reflecting ongoing efforts to expand patient access amid pricing policy pressures.

Looking Ahead

Investors are closely monitoring pipeline expectations and valuation frameworks for major pharmaceutical names as analysts reset price targets based on updated product portfolios. Tandem Diabetes Care's 2026 Mobi tubeless launch will be a key milestone to watch in the diabetes device market. Broader sector attention remains on how drug pricing policy developments and Medicare negotiations will impact commercial strategies for weight-loss and specialty drugs.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy